---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007750"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:16:23.730353+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals' MGX-0024 zero respiratory mortality in 29,000-bird trial; 60% H5N1 mortality cut

## Summary
- Three commercial field trials in India (~29,000 broilers) with MGX-0024 drinking water showed zero respiratory-related mortality vs. historical ~50%.
- Controlled H5N1 challenge (ICAR-NIHSAD): 48-hr pre-treatment reduced mortality 60% (2/7 vs 5/7 deaths) and extended mean time to death to 10.71 days.
- Surviving birds in H5N1 study were seronegative for H5 antibodies at day 14, suggesting early interference with infection establishment.
- MGX-0024 is a GRAS-classified polyphenol/zinc formulation forming respiratory barrier; protected by US Patent 11,517,523 and international patents.
- Company scaling production, pursuing regulatory discussions in US, UK, Australia, and targets commercial rollout in select markets.

## SEC filing metadata
- accession: 0001493152-26-007750
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315226007750/0001493152-26-007750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315226007750/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007750
- JSON: https://secwatch.observer/filing/0001493152-26-007750.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.